Brought to you by 
Takeda to buy Intellikine for $190mm plus earn-outs
22 Dec 2011
Executive Summary
Takeda Pharmaceutical Co. Ltd. has offered $190mm in cash to acquire privately held oncology and inflammation therapeutics company Intellikine Inc. An additional $120mm in earn-outs could be tacked on if certain clinical development milestones are met.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com